Eric Dollins, PhD Adaptimmune, LLC

Eric Dollins, PhD has been in the field of cell & gene therapies for the last almost 15 years in a variety of capacities, including at roles at a health authority (US FDA) and in industry. After completing a PhD in biochemistry and a post-doc in molecular cancer biology, Eric joined FDA’s CBER/OTP/Division of Cellular & Gene Therapies first as a Commissioner's Fellow, then as product reviewer, and finally as team lead before transitioning to industry. Within industry, Eric has had numerous roles in both global biopharma and biotech, as well as independent regulatory affairs consultancy. In global biopharma these roles have included: Global Regulatory Lead (GRL), GRA Interim Therapeutic Area Head, and Head of Search & Evaluation, CMC Biologics and Early Development Technologies within External Innovation. As an independent regulatory affairs consultant, Eric has had the opportunity to provide expert scientific, regulatory, and strategic advice for the development of a variety of cell & gene therapy products. Mostly recently, Eric has served as Head of Global Regulatory Affairs at two different biotechs, including his current role at Adaptimmune.